image credit: Freepik

Allergen builds case for first drug therapy for presbyopia

July 26, 2021


Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie’s Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation – codenamed AGN-190584 – at the American Society of Cataract and Refractive Surgery (ASCRS) congress over the weekend.

Pilocarpine is a muscarinic cholinergic agonist that is already used to reduce pressure inside the eye in ophthalmic diseases like glaucoma, but has only recently been repurposed for the long-sightedness – caused by a stiffening of the lens – that develops in people after the age of 40.

Read More on Pharmaphorum